Leo Pharma and Astrazeneca keep future plans tight for tralokinumab

Neither Leo Pharma nor Astrazeneca wants to reveal the future plans for tralokinumab, which has just been approved as an atopic eczema treatment in the US. The drug has blockbuster potential in the approved indication, and while other indications might be considered, Astrazeneca retains the rights for several lucrative indications.

Jörg Möller, head of global research and development at Leo Pharma, doesn't have a lot to say when it comes to Leo Pharma's hopes for tralokinumab besides atopic eczema

The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs